Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Active, not recruiting · NCT06180733 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-05-01 | NCT06180733 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| University Medical Center Groningen | 213 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Medical Centre Groningen | Groningen | Netherlands | 1 |